Background
Most substance use disorders (SUD) treatment clinical trials are too short and small to reliably estimate the incidence of rare events like death.
Objective
The aim of this study is to estimate the overall mortality rates among a SUD treatment-seeking population by pooling participants from multiple clinical trials conducted through the National Institute on Drug Abuse (NIDA)-sponsored National Drug Abuse Treatment Clinical Trials Network (CTN).
Highlights
•Standardized mortality (SM) rate among substance abuse trials was assessed.
•Standardized mortality (SM) ratio among substance abuse trials was assessed.
•SM rate of substance abuse trial population is higher than general population.
•SM ratio of substance abuse trial population is higher than general population.